40 Participants NeededMy employer runs this trial

HMS1005 for Type 2 Diabetes

JO
Overseen ByJesus Olivia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes

Are You a Good Fit for This Trial?

Inclusion Criteria

8. Fasting plasma glucose between 126 and 240 mg/dL, inclusive. Testing may be repeated once, at the discretion of the Investigator (or designee).
I understand the study and am willing to sign consent and follow its rules.
2. Body mass index between 18 and 38.0 kg/m2, inclusive.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive multiple ascending doses of HMS1005 or placebo to evaluate safety, pharmacokinetics, and pharmacodynamics

19 days
Daily visits for dosing and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • HMS1005

How Is the Trial Designed?

5

Treatment groups

Experimental Treatment

Group I: 492 mg HMS1005 (2 x 246 mg tablet) and matching placeboExperimental Treatment2 Interventions
Group II: 369 mg HMS1005 (2 x 184.5 mg tablet) and matching placeboExperimental Treatment2 Interventions
Group III: 246 mg HMS1005 (1 x 246 mg tablet) or placeboExperimental Treatment2 Interventions
Group IV: 184.5 mg HMS1005 (1 x 184.5 mg tablet) and matching placeboExperimental Treatment2 Interventions
Group V: 123 mg HMS1005 (1 x 123 mg tablet) and matching placeboExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hua Medicine Limited

Lead Sponsor

Trials
16
Recruited
3,800+

TigerMed

Industry Sponsor

Trials
4
Recruited
1,100+